Telum raises €18M for hospital infection treatments
Telum Therapeutics raised an €18M Series A to advance protein-based antimicrobial treatments for serious hospital infections.
Antimicrobial resistance is one of healthcare’s hardest funding problems: the need is serious, but the market is difficult.
What happened
Spanish biotech Telum Therapeutics raised an €18M Series A to advance its lead programme for serious hospital-acquired infections.
The round was led by AMR Action Fund, with participation from Inveready, Invivo Partners, CDTI / SICC Innvierte, Clave Capital and Sodena. Telum is developing protein-based antimicrobial therapeutics through its APEX platform.
Why it matters
Hospital-acquired infections are a major healthcare burden, especially when existing treatments become less effective.
Telum’s approach is interesting because it focuses on new antimicrobial mechanisms rather than another incremental treatment. That matters in a category where the world needs more options, but biotech funding can be hard to secure.
The bigger picture
Life sciences capital often follows large commercial markets, but antimicrobial resistance is also a public-health infrastructure problem.
Telum’s round shows that specialist investors are still willing to back companies working on difficult infection categories when the science, clinical need and funding support align.